
Opinion|Videos|April 14, 2026
ADCs and Early-Stage HER2+ Breast Cancer Care
Author(s)Neil Iyengar, MD, Kelsey Natsuhara, MD
Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how antibody-drug conjugates have altered the HER2-positive breast cancer treatment paradigm.
Advertisement
Episodes in this series

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss the evolving role of antibody-drug conjugates (ADCs) in early-stage HER2-positive breast cancer. Iyengar highlights how these agents may serve as escalation strategies for high-risk patients in neoadjuvant and adjuvant settings. Natsuhara emphasizes the importance of weighing toxicity considerations and the potential downstream impact on treatment options in the metastatic setting.
Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
5

